- Home
- PCVX vs IBRX Comparison
PCVX vs IBRX Comparison
Compare PCVX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | IBRX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 8.2B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PCVX | IBRX |
|---|---|---|
| Price | $71.60 | $10.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $117.00 | $12.75 |
| AVG Volume (30 Days) | 2.9M | ★ 10.5M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | N/A | $99.26 |
| Revenue Next Year | N/A | $101.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $39.87 | $1.95 |
| 52 Week High | $90.75 | $12.43 |
Technical Indicators
Market Signals| Indicator | PCVX | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 69.13 |
| Support Level | $48.67 | $6.68 |
| Resistance Level | N/A | $12.43 |
| Average True Range (ATR) | 4.55 | 0.59 |
| MACD | 1.33 | 0.16 |
| Stochastic Oscillator | 47.82 | 90.04 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.